



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, November 14th, 2022

To
The General Manager,
Listing Department,
Bombay Stock Exchange Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai- 400001

Dear Sir/Ma'am,

Sub: Financial Results for the quarter ended 30th September, 2022 – Regulation 33 (3) (a).

Ref: Company Scrip Code: 524711


With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Monday, 14th November, 2022 at 01.00 P.M. at the corporate office of the Company, interalia, considered and approved the unaudited Financial Results for the quarter ended 30th September, 2022.

Copy of un-audited Financial Results for the quarter ended 30th September, 2022 and Limited review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,


For Vista Pharmaceuticals Limited



DHANANJAYA ALLI

WHOLETIME DIRECTOR

DIN: 00610909



VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2022

(in Rs Lakhs)


| S.No | Particulars | Quarter ended | | | Half- Year ended | | Year ended |
|------|---|----------------------|----------------|----------------------|----------------------|----------------------|------------------|
| | | September 30,2022 | June 30,2022 | September 30,2021 | September 30,2022 | September 30,2021 | March 31,2022 |
| | | Un Audited | Un Audited | Un Audited | Un Audited | Un Audited | Audited |
| 1 | Income | | | | | | |
| | a. Revenue from operations | - | 0.00 | 28.54 | | 28.54 | 39.46 |
| | b. Other income | - | - | (4.64) | | -7.61 | 16.57 |
| 2 | Total Income (a+b) | 0.00 | 0.00 | 23.90 | 0.00 | 20.93 | 56.03 |
| 3 | Expenses | | | | | | |
| | a) Cost of Material Consumed | - | - | 0.00 | 0.00 | 1.26 | 36.66 |
| | b) Change in Inventories | - | - | 26.40 | 0.00 | 26.40 | - |
| | c) Employee benefits expense | 2.60 | 5.10 | 19.17 | 7.70 | 39.02 | 57.48 |
| | d) Finance costs | 25.70 | 23.78 | 20.74 | 49.48 | 34.58 | 89.98 |
| | e) Depreciation and amortization expense | 15.40 | 15.40 | 15.40 | 30.80 | 31.09 | 61.62 |
| | f) Other expenses | 12.25 | 15.05 | 13.47 | 27.30 | 35.77 | 66.37 |
| | Total Expenses | 55.95 | 59.33 | 95.18 | 115.28 | 168.12 | 312.11 |
| 4 | Profit before tax (2-3) | (55.95) | (59.33) | (71.28) | -115.28 | -147.19 | -256.08 |
| 5 | Tax expense | | | | | | |
| | (1) Current tax | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| | (2) Deferred tax | (31.96) | (0.30) | 147.77 | -32.26 | 83.51 | (172.90) |
| 6 | Net Profit for the Period (4-5) | (23.99) | (59.03) | (219.05) | -83.02 | -230.70 | (83.18) |
| 7 | Other comprehensive income (OCI) | | | | | | |
| | (a) (i) Items that will not be reclassified to profit or loss | | - | | | | - |
| | (ii) Tax on items that will not be reclassified to profit or loss | | - | - | - | - | - |
| | (b) (i) Items that will be reclassified to profit or loss | (7.24) | (8.56) | - | (15.80) | - | (6.68) |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | | - | - | - | - | - |
| | Total Other Comprehensive income | (7.24) | (8.56) | - | (15.80) | - | (6.68) |
| 8 | Total Comprehensive income (6+7) | (31.23) | (67.59) | -219.05 | -98.82 | -230.70 | -89.86 |
| | Earnings per equity share | | | | | | |
| | (Face value of Rs.2/- each) | | | | | | |
| | (1) Basic | -0.08 | -0.18 | -0.60 | -0.27 | -0.34 | -0.24 |
| | (2) Diluted | -0.08 | -0.18 | -0.60 | -0.27 | -0.34 | -0.24 |
| | Paid- up equity share capital(Face Value of Rs.2/- each) | 735.88 | 735.88 | 735.88 | 735.88 | 735.88 | 735.88 |

Notes:


- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- 2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 14th November , 2022
- 3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
4. Total Income for the current quarter reported NIL compared to Rs.28.54 Lakhs for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs.56.55 Lakhs compared to Loss Before tax of Rs. 95.18 Lakhs for the corresponding quarter of the previous year.
- 8.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 9.The results for the quarter ended 30th September 2022 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
- 10.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.



Place:Hyderabad
Date:14.11.2022

For Vista Pharmaceuticals Limited



DHANANJAYA ALLI
Wholetime Director
(DIN: 00610909)



| VISTA PHARMACEUTICALS LIMITED Registered Office : Gopalaipalli(Village),Narketpalli(Mandal),Nalgonda Dist.T.S. - 508254 (CIN: L24239TG1991PLC012264) STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30th Sep, 2022 | | |
|---|-----------------|-------------|
| | (Rs.in Lakhs) | |
| Particulars | September ,2022 | March ,2022 |
| Cash Flows from Operating Activities | | |
| Net profit before tax | (115.28) | (256.09) |
| Adjustments for : | | |
| Depreciation and amortization expense | 30.81 | 61.62 |
| Unrealised Foreign Exchange Gain/Loss | (15.80) | (6.68) |
| Gain on investments carried at fair value through profit or loss | (0.77) | 0.00 |
| Interest & Finance Charges Paid | 49.48 | 89.98 |
| Operating profit before working capital changes | (51.56) | (111.16) |
| Movements in Working Capital | | |
| (Increase)/Decrease in Inventories | 0.00 | 35.40 |
| (Increase)/Decrease in Other financial assets | 0.00 | 0.00 |
| (Increase)/Decrease in Trade Receivables | 11.94 | (40.24) |
| (Increase)/Decrease in Other Current Assets | (33.72) | (12.32) |
| (Increase)/Decrease in Other Non Current Assets | 0.00 | (0.00) |
| Increase/(Decrease) in Trade Payables | 40.83 | 26.16 |
| Increase/(Decrease) in Other financial liabilities | 0.00 | 0.00 |
| Increase/(Decrease) in Other Current liabilities | (2.49) | 2.86 |
| Increase/(Decrease) in Other Non Current liabilities | 0.00 | 0.00 |
| Increase/(Decrease) in Provisions | 0.00 | 0.01 |
| Changes in Working Capital | 16.57 | 11.86 |
| Cash generated from operations | (34.98) | (99.30) |
| Direct Taxes Paid | - | - |
| Net Cash from operating activities (A) | (34.98) | (99.30) |
| Cash flows from Investing Activities | | |
| Purchase of Fixed Assets (Including CWIP) | - | (1.43) |
| Intangible Assets | 0.00 | 0.00 |
| Net Cash used in Investing Activities | 0.00 | (1.43) |
| Cash flows from/(used in) Financing Activities | | |
| Issue of Share Capital | - | - |
| Issue of Share Warrants | - | - |
| Proceeds from Long term borrowings | (50.70) | 67.44 |
| Repayment/Proceeds of/from Short-term borrowings | 135.16 | 116.47 |
| Interest paid | (49.48) | (89.98) |
| Net Cash used in Financing Activities | 34.98 | 93.93 |
| Net Increase/(Decrease) in cash and cash equivalents | (0.00) | (6.80) |
| Cash and Cash equivalents at the beginning of the year | 7.20 | 14.00 |
| Cash and Cash equivalents at the ending of the year | 7.20 | 7.20 |
| <div style="display: flex; justify-content: space-between;"> <div> Place:Hyderabad Date:14.11.2022 </div> <div> FOR VISTA PHARMACEUTICALS LIMITED For Vista Pharmaceuticals Limited  DHANANJAYA ALLI Wholetime Director (DIN: 00610909) </div> <div>  </div> </div> | | |

VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

STANDALONE STATEMENT OF ASSETS AND LIABILITIES


(Rs. In lakhs)

| S No | Particulars | As at 30th September 2022 | As at 31st March 2022 |
|-----------|--|------------------------------|--------------------------|
| | | (Un Audited) | (Audited) |
| I. | ASSETS | | |
| | Non-current assets | | |
| (a) | Property, Plant and Equipment | 947.04 | 977.85 |
| (b) | Capital work-in-progress | 908.27 | 908.27 |
| (c) | Intangible assets | 955.30 | 955.30 |
| (d) | Financial Assets | - | - |
| | (i) Investments | 2.36 | 3.13 |
| | (ii) Other Financial Assets | 10.00 | 10.00 |
| (e) | Deferred tax assets (Net) | 380.14 | 348.18 |
| (f) | Other Non-Current Assets | 821.74 | 821.74 |
| | Total Non - Current Assets | 4,024.86 | 4,024.48 |
| | Current assets | | |
| (a) | Inventories | 932.75 | 932.75 |
| (b) | Financial assets | - | - |
| | (i) Investments | - | - |
| | (ii) Trade receivables | 245.22 | 257.16 |
| | (iii) Cash and Bank equivalents | 7.18 | 7.19 |
| | (iv) cash and cash equivalent (other than above) | - | - |
| (c) | Other current assets | 371.10 | 337.39 |
| | Total Current Assets | 1,556.26 | 1,534.49 |
| | Total Assets | 5,581.12 | 5,558.97 |
| II | EQUITY AND LIABILITIES | | |
| | Equity | | |
| (a) | Equity Share capital | 735.88 | 735.88 |
| (b) | Other equity | 2,710.59 | 2,809.41 |
| | Total Equity | 3,446.47 | 3,545.29 |
| | Liabilities | | |
| | Non-current liabilities | | |
| (a) | Financial Liabilities | | |
| | (i) Borrowings | 886.03 | 936.73 |
| | (ii) Other financial liabilities | - | - |
| (b) | Deferred tax liabilities (Net) | - | - |
| (c) | Provisions | 7.17 | 7.17 |
| | Total Non - Current Liabilities | 893.20 | 943.89 |
| | Current liabilities | | |
| (a) | Financial Liabilities | | |
| | (i) Borrowings | 453.54 | 318.38 |
| | (ii) Trade payables | 577.49 | 536.66 |
| | (iii) Other financial liabilities | 5.30 | 5.30 |
| (b) | Current Tax Liabilities (Net) | - | - |
| (c) | Provisions | 23.62 | 23.62 |
| (d) | Other current liabilities | 181.50 | 185.83 |
| | Total Current Liabilities | 1,241.45 | 1,069.78 |
| | Total Equity and Liabilities | 5,581.12 | 5,558.97 |


Place: Hyderabad

Date: 14. 11. 2022

For Vista Pharmaceuticals Limited



DHANANJAYA ALLI
Wholtime Director
(DIN: 00610909)





A.M. REDDY & D.R. REDDY
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on unaudited Quarterly Financial results of
VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Vista Pharmaceuticals Limited.


1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited ("the Company") for the quarter ended September 30, 2022 and year to date results for the period June 30, 2022 to September 30, 2022 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in

accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A M Reddy & D R Reddy
Chartered Accountants

FRN : 009068S


D Ramakrishna Reddy
Partner

M.No.209211

UDIN: 22209211BDBUNW3681



Place : Hyderabad

Date: 14/09/2022